

Market Announcement

23 February 2024

Allegra Medical Technologies Limited (ASX: AMT) – Suspension from Quotation

Description

The securities of Allegra Medical Technologies Limited ('AMT') will be suspended from quotation immediately under Listing Rule 17.2, at the request of AMT, pending the release of an announcement regarding its funding arrangements and sale process relating to the Sr-HT-Gahnite Spinal Cage Device critical to its continued financial viability.

Issued by

ASX Compliance



23 February 2024

Lisa Banh, Senior Adviser, Listings Compliance (Sydney) Australian Securities Exchange 20 Bridge Street, Sydney NSW 2000

Dear Lisa,

Allegra Medical Technologies Limited (ASX: AMT) - Request for Voluntary Suspension

Allegra Medical Technologies Limited ACN 066 281 132 (**Company**) refers to the request for a trading halt on 21 February 2024 pending an announcement to be released to the ASX by the Company in relation to discussions with its financiers (**Announcement**).

Pursuant to ASX Listing Rule 17.2, the Company requests a voluntary suspension of trading in its securities effective immediately.

In accordance with ASX Listing Rule 17.2, the Company advises as follows:

(a) The voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations whilst the Company finalises the ongoing discussions with its lenders in relation to the Company's funding requirements.

As announced on 6 February 2024, the Company announced it is going to the market to seek a buyer for all of the intellectual property relating to the Sr-HT-Gahnite Spinal Cage Device, including worldwide patents and all registered patents and application for patents in relation to the bio ceramic material, including the spinal fusion cage. The Company confirms that in undertaking taking this process any proposed sale will be subject to the required ASX and regulatory approvals (Sale Process).

The Company has commenced, and is progressing, this Sale Process.

However as the Sale Process is expected to take some months, including seeking buyers, negotiating and completion of any necessary ASX and regulatory requirements, the Company is reliant on the continued support of its current financiers during this Sale Process.

That continued support of the financiers is presently being discussed, negotiated, and assuming satisfactory terms can be agreed, documented. This is envisaged to take up to 2 weeks. Should these discussions complete earlier, the Company will advise the market at that time and seek lifting of the suspension at that time.

Successful completion of both the continued support of its current financiers and the Sale Process is critical to the Company's continued financial viability. In the Company's opinion, continued trading of its securities is likely to materially prejudice its ability to complete the discussions with its current financiers during that process.

Allegra Medical Technologies Limited

Level 8, 18 --- 20 Orion Rd, Lane Cove West NSW 2066 Australia; PO Box 72 St Leonards NSW 2065 Australia

T+612 9119 9200 T Toll Free 1800 644 370

F+612 9439 4441 F Toll Free 1800 624 223

E sales@allegraorthopaedics.com



- (b) As such, the Company requests that the voluntary suspension continues until the earlier of the Company releasing the Announcement, or until the close of normal trading on Friday, 8th March 2024.
- (c) The Company expects that the voluntary suspension will be ended by making the Announcement.
- (d) The Company is not aware of any reason why its securities should not be suspended, or of any other information available at this stage that is relevant to the voluntary suspension.

For and on behalf of the Board of Allegra Medical Technologies Limited.

Yours faithfully,

Robyn Slaughter Company Secretary